Stay updated with breaking news from Efficacy Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 13, 2023
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023
12.04.2023 - Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements ... Seite 1
DEVON, Pa., April 05, 2023 -- Zynerba Pharmaceuticals, Inc. , the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today... | April 5, 2023
28.02.2023 - Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on ... Seite 1